|
Dr. Street was appointed Senior Director, Medicinal Chemistry in March 2007. Dr. Street, who was previously Senior Director, Head of Medicinal Chemistry at Renovis, also has more than twenty years experience at Merck’s Neuroscience Research Center in the United Kingdom, a division of Merck, Inc. During his tenure at Merck, Dr. Street was focused on drug discovery programs for treating migraine, cognitive disorders, anxiety, and schizophrenia. He led medicinal chemistry teams that were successful in advancing several clinical candidates in the CNS disease area, including most recently the anti-migraine drug Rizatriptan (MAXALT®), which was approved by the FDA in 1998. Dr. Street has published nearly 50 peer-reviewed manuscripts and over 80 patents.
Dr. Street received both B.S. and Ph.D. degrees from Leeds University and performed post-doctoral studies at the University of California, Los Angeles. | 